NCT04414124

A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19

A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 350 (actual)
• Sponsor: Kaleido Biosciences · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of health in outpatients with mild-to-moderate COVID-19.

Conditions

• Mild-to-moderate COVID-19

Interventions

Type	Name	Description
OTHER	KB109 + Self Supportive Care (SSC)	KB109 is a novel glycan
OTHER	Self Supportive Care (SSC) Alone	Self Supportive Care (SSC) Alone

Timeline

• Start date: 2020-08-02
• Primary completion: 2021-02-02
• Completion: 2021-02-02
• First posted: 2020-06-04
• Last updated: 2021-08-13

Locations

16 sites across 1 country: United States